Penthrox Regulatory Dossier accepted for review in Canada
Filed with ASX · · 2 pages · English
Penthrox Regulatory Dossier accepted for review in Canada Medical Developments International Limited (ASX: MVP) is delighted to announce that the regulatory dossier for Penthrox® submitted in Canada has now been accepted for review by the Canadian regulatory body, Health Canada. Accepting the MVP dossier for review, triggers a milestone payment of CAD$0.25 million from MVP’s partner, Purdue Pharma
Medical Developments International Limited on 6ix
Story so far
Earlier from Medical Developments International
- MVP signs significant Development Project with CSIRO
- Penthrox replaces Nitrous Oxide in New Zealand Ambulance
- MVP Respiratory devices now available in USA Costcos
- Penthrox Licensing Deal for Russia
- MVPs Respiratory Devices in all Kmart pharmacies in the USA
Later from Medical Developments International
- MVP signs Respiratory Device supply deal with Sams Club
- 1st patient enrolled in Penthrox paediatrics trial in Europe
- Penthrox recommended for use in all UK ambulances
- Chairman sells 4.35 million shares
- Penthrox approved in Mexico
Follow Medical Developments International into a list and get an email when it puts out news.
Follow Medical Developments International